Oliver Van Oekelen

Excited as co-first author to share our NEJM case report: we describe the successful personalized treatment of a CAR⁺ T-cell lymphoma that developed after anti-BCMA CAR T therapy for multiple myeloma. A remarkable example of precision medicine in action. #mmsm #MultipleMyeloma

🚨Just out @JNCI_Now, we review 20 years of RCTs in myeloma for lessons in drug development. Surprisingly, head-to-head trials were as likely to be successful as add-on trials. academic.oup.com/jnci/advance-a… #mmsm #myeloma @ManniMD1

By understanding and targeting these pathways, we aim to improve the durability of immune therapies and patient outcomes. Excited to continue this journey with incredible colleagues and collaborators in the myeloma research community: @Amitvermamds @TischCancer @IcahnMountSinai

Grateful for the opportunity to share our progress and vision for better treatments. Our research focuses on how proteins like S100A8/A9 shape immune microenvironment and drive immune suppression and T-cell dysfunction: critical challenges for CAR-T and bispec antibody therapies.

Thank you @HealthTree and @MyelomaTeacher for giving me the chance to discuss our work in multiple myeloma #mmsm: we aim to modulate the immune microenvironment to improve T cell-directed therapy.

Thank you @MyelomaSociety for recognizing our work with the Young Investigator Award this year! I’m grateful to my mentors, collaborators, and patients who inspire this research every day. Excited to keep pushing boundaries in #MultipleMyeloma research. #mmsm

I’m grateful to the OncLive team for this platform, and to all the collaborators, patients, and mentors who make this work possible. @IcahnMountSinai @DOMSinaiNYC

By promoting an immunosuppressive niche, S100A8/A9 contributes to resistance against CAR-T and bispecific antibodies. Understanding this biology opens the door to new strategies to enhance immunotherapy efficacy in myeloma. Check out other top videos: onclive.com/view/five-unde…

Honored to be featured in @OncLive’s Five Under 5: Top Oncology Videos. I shared our work on S100A8/A9 in multiple myeloma, a DAMP released by myeloid cells that drives T-cell exhaustion. 🎥 onclive.com/view/dr-van-oe… #FiveUnder5 #Myeloma #mmsm

It's time for the #FiveUnder5 🕒. Check out the top #oncology videos of the week 📷: onclive.com/view/five-unde… @HOGONC @DanaFarber @harvardmed @stolaney1 @efratdotan @LGHealth @ovanoekelen @IcahnMountSinai @RaabMarc @HDMyeloma #bcsm #pancsm #mmsm #medtwitter

Thank you to @ovanoekelen for joining us at #IMS25 to discuss how S100A8/A9 promotes T-cell exhaustion and impacts responses to bispecific therapy in multiple myeloma 🔬 #MultipleMyeloma #CellTherapy Tune in for our latest conference coverage! onclive.com/conference/imw

Our #MultipleMyeloma doctors are presenting on September 17 at #IMS25, @Myeloma_Society @tarekmd91 @JoshuaRichterMD @ovanoekelen Adolfo Aleman @IcahnMountSinai

.@ovanoekelen discusses first targeted/personalized treatment of a CAR⁺ T-cell lymphoma that developed after anti-BCMA CAR T-cell therapy for #MultipleMyeloma. oncodaily.com/insight/oliver…

Here is the link to the full article: nejm.org/doi/10.1056/NE…

Honored to contribute to work that not only addresses challenges in CAR T therapy but also underscores the power of translational science and teamwork. Excited to continue building toward safer and more effective therapies for patients with blood cancers as a heme/onc fellow.

Excited as co-first author to share our NEJM case report: we describe the successful personalized treatment of a CAR⁺ T-cell lymphoma that developed after anti-BCMA CAR T therapy for multiple myeloma. A remarkable example of precision medicine in action. #mmsm #MultipleMyeloma

Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy | New England Journal of Medicine nejm.org/doi/full/10.10… From Samir Parekh and colleagues at @IcahnMountSinai